Compare · MDLN vs NYXH
MDLN vs NYXH
Side-by-side comparison of Medline Inc. (MDLN) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 403.7x NYXH ($119.1M).
- Over the past year, MDLN is down 11.8% and NYXH is down 81.1% - MDLN leads by 69.4 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 3 for NYXH).
- MDLN has more recent analyst coverage (25 ratings vs 9 for NYXH).
PerformanceMDLN-11.77%NYXH-76.36%
2025-12-17+0.00%2026-10-16
- Company
- Medline Inc.
- Nyxoah SA
- Price
- $35.95-1.74%
- $1.13-5.44%
- Market cap
- $48.08B
- $119.1M
- 1M return
- +11.97%
- -24.16%
- 1Y return
- -11.77%
- -81.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 7
- 3
- Recent ratings
- 25
- 9
NYXH
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest NYXH
- Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Appoints Liam Kelly as Chief Executive Officer
- SEC Form 6-K filed by Nyxoah SA
- CVRx Appoints John Landry as Chief Financial Officer
- Nyxoah Announces Chief Financial Officer Transition
- Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
- Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
- Information on the total number of voting rights and shares
- Amendment: SEC Form SCHEDULE 13G/A filed by Nyxoah SA